Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

盘前交易 06-01 09:03:09 EDT

17.87

+0.57

+3.29%

盘前17.88

+0.01+0.06%

09:01 EDT

最高17.99	最低17.42	成交量365.46万
今开17.42	昨收17.30	日振幅3.29%
总市值18.87亿	流通市值16.70亿	总股本1.06亿
成交额6,512万	换手率3.91%	流通股本9,346万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":17.87,"timestamp":1780084800000,"preClose":17.3,"halted":0,"volume":3654619,"hourTrading":{"tag":"盘前","latestPrice":17.88,"preClose":17.87,"latestTime":"09:01 EDT","volume":3688,"amount":66302.030512,"timestamp":1780318876343,"change":0.01,"changeRate":0.00056,"amplitude":0.022888},"delay":0,"changeRate":0.032947976878612735,"floatShares":93464700,"shares":105571146,"eps":0.637648,"marketStatus":"盘前交易","change":0.57,"latestTime":"06-01 09:03:09 EDT","open":17.42,"high":17.99,"low":17.42,"amount":65124711.22248399,"amplitude":0.032948,"askPrice":17.88,"askSize":121,"bidPrice":17.78,"bidSize":1,"shortable":3,"etf":0,"ttmEps":0.637648,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780320600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":865396800000,"exchange":"NASDAQ","adjPreClose":17.87,"preHourTrading":{"tag":"盘前","latestPrice":17.88,"preClose":17.87,"latestTime":"09:01 EDT","volume":3688,"amount":66302.030512,"timestamp":1780318876343,"change":0.01,"changeRate":0.00056,"amplitude":0.022888},"postHourTrading":{"tag":"盘后","latestPrice":17.9,"preClose":17.87,"latestTime":"19:15 EDT","volume":553016,"amount":9881717.2582,"timestamp":1780096556915,"change":0.03,"changeRate":0.001679,"amplitude":0.039519},"volumeRatio":1.4981984487890287,"impliedVol":0.531,"impliedVolPercentile":0.044},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"1118932123","title":"财报前瞻｜Sarepta Therapeutics本季度营收预计同比下降30.61%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1118932123","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118932123?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:46","pubTimestamp":1777448804,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics将于2026年05月06日发布财报，市场关注本季营收与盈利拐点的同步出现及基因疗法商业化节奏。市场一致预期本季度公司营收为4.74亿美元，同比下降30.61%；调整后每股收益为0.99美元，同比上升204.75%，显示在收入同比承压的前提下，盈利端有望出现显著改善；公司上季度未披露本季度的收入或利润指引。公司当前主营由产品销售贡献3.70亿美元，占比83.45%，在整体营收同比下降32.73%的环境下，核心商业化产品仍是基本盘。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Sarepta Therapeutics本季度营收预计同比下降30.61%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1153818821","title":"ETF日报｜2倍做多Firefly Aerospace ETF涨超36%；2倍做多Arm ETF涨超32%；成长科技与贵金属双强","url":"https://stock-news.laohu8.com/highlight/detail?id=1153818821","media":"ETF追踪","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153818821?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:25","pubTimestamp":1774491900,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多SRPT ETF-Tradr$上涨69.23%。Sarepta Therapeutics周三大涨近35%，此前该公司公布了两项治疗罕见肌肉萎缩症的初步数据。该产品两倍做多航空航天公司$Firefly Aerospace$，标的股价上行带动产品大幅走高，杠杆效应放大收益。有报道称埃隆马斯克旗下的SpaceX最快将于本周提交上市申请，周三太空概念股应声飙升，Firefly Aerospace涨超16%，Intuitive Machines涨近15%，Planet Labs涨超11%，Rocket Lab和AST SpaceMobile涨超10%。$2倍做多ARM ETF- Leverage Shares$上涨32.51%。$罗素2000指数三倍做多ETF-Direxion$上涨3.63%。债券ETF涨幅Top 5$Infracap REIT Preferred ETF$上涨1.33%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3708dfae7df7b402c74cc0c9fcc664e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DKNG","XPP","DAMD","CHAU","SRPU","EDC","RKLB","FLYT","TLT","AGQ","FLY","ARM","LUNL","SLV","ASTN","RKLZ","SPTL","NUGT","UGL","UYM","DGP","AMD","TAN","SMCI","ARMG","EMB","IBB","TNA","PLU","NLR","SMCZ","SRPT","PFFR","LUNR","DKNX","YINN","PCY","SOXL","ASTS","PL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127376048","title":"Sarepta Therapeutics飙升逾25%！肌肉疾病药物早中期试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1127376048","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127376048?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:51","pubTimestamp":1774446665,"startTime":"0","endTime":"0","summary":"3月25日，$Sarepta Therapeutics(SRPT)$盘初飙升逾25%！该公司肌肉疾病药物早中期试验结果积极。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22d97c574d1b8881ace253d280e1b6b5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","BK4539","SRPT","BK4139","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","BK4007","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106360538","title":"Sarepta Therapeutics股价盘前上涨3.2%，肌肉疾病药物早中期试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1106360538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106360538?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:30","pubTimestamp":1774441857,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics的股价在盘前交易中上涨了3.2%，这一上涨源于其针对肌肉疾病的药物在早中期临床试验中显示出积极前景。试验数据的乐观信号提振了投资者信心，市场对该药物后续研发进展抱以期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPU","SRPT","BK4585","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4139","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161884966","title":"Sarepta Therapeutics：研究中多数不良事件为轻至中度且与剂量无关","url":"https://stock-news.laohu8.com/highlight/detail?id=1161884966","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161884966?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:06","pubTimestamp":1774440394,"startTime":"0","endTime":"0","summary":"在Sarepta Therapeutics进行的研究中，所观察到的不良事件大多呈现轻度至中度表现，且未显示出剂量依赖性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","SRPT","SRPU","BK4585","IE00B2B36J28.USD","IE0009355771.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193886488","title":"Sarepta Therapeutics概念验证数据：单剂量SRP-1001与SRP-1003可降低靶蛋白或mRNA水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1193886488","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193886488?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:06","pubTimestamp":1774440383,"startTime":"0","endTime":"0","summary":"最新概念验证研究数据显示，Sarepta Therapeutics研发的SRP-1001和SRP-1003在单次给药后，能有效降低目标蛋白或信使核糖核酸（mRNA）的表达水平。这一突破性进展为相关疗法的后续开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22d97c574d1b8881ace253d280e1b6b5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","SRPU","BK4585","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE0002141913.USD","SRPT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100608630","title":"FDA确认Sarepta可提交Essence研究及真实世界证据用于新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1100608630","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100608630?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:32","pubTimestamp":1773923522,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式批准Sarepta Therapeutics公司提交其Essence临床研究数据及真实世界证据，作为支持新药申请的关键材料。这一决定为Sarepta推进相关疗法审批流程扫清了重要障碍。FDA的认可标志着监管机构对创新证据采集方式的开放性态度，也为生物技术行业树立了新的审评标准。公司表示将按计划提交完整数据包，并与FDA保持密切沟通以推进后续流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4585","SRPU","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4139","SRPT","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111209231","title":"Sarepta Therapeutics 请求与FDA会面 探讨提交补充新药申请事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1111209231","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111209231?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:31","pubTimestamp":1773923518,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc. 已正式向美国食品药品监督管理局（FDA）提出会面请求，旨在讨论提交补充新药申请（sNDA）的相关事宜。此次会议将聚焦于新药申请材料的准备与提交策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BJJMRZ35.SGD","BK4139","SRPU","IE00B2B36J28.USD","SRPT","IE0009355771.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614962868","title":"Sarepta Therapeutics, Inc.盘中异动 股价大跌5.21%报16.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614962868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614962868?lang=zh_cn&edition=full","pubTime":"2026-02-28 03:15","pubTimestamp":1772219710,"startTime":"0","endTime":"0","summary":"北京时间2026年02月28日03时15分，Sarepta Therapeutics, Inc.股票出现波动，股价大幅下跌5.21%。截至发稿，该股报16.54美元/股，成交量134.941万股，换手率1.29%，振幅3.90%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.08%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228031510a727cf58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228031510a727cf58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SRPU","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LENZ","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4007","BK4539","IE0002141913.USD","SRPT","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127234068","title":"Sarepta Therapeutics启动第九届Route 79杜氏肌营养不良症奖学金计划申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1127234068","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127234068?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:01","pubTimestamp":1772200874,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布正式开放第九届Route 79杜氏肌营养不良症奖学金项目的申请通道。该项目旨在为受杜氏肌营养不良症影响的杰出学生提供教育支持，助力其追求学术与职业发展梦想。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SRPU","SRPT","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153249938","title":"ETF日报｜2倍做多IONQ ETF涨超42%；三倍做多金融指数ETF涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153249938","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153249938?lang=zh_cn&edition=full","pubTime":"2026-02-27 08:43","pubTimestamp":1772153022,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多IONQ ETF-Defiance$上涨42.35%。$2倍做空IONQ ETF-Defiance$下跌43.30%。该产品三倍做空富时中国指数，相关多头产品走弱带动其逆向上涨。该产品三倍做空纳斯达克指数，因纳斯达克指数当日回落，反向杠杆产品获得涨幅。大宗商品ETF涨幅Top 5$二倍做多黄金矿业指数ETF-Direxion$上涨5.08%。该产品跟踪小市值黄金矿业公司，相关成分股普遍上行带动ETF上涨。行业指数ETF涨幅Top 5$金融指数ETF-Direxion三倍做多罗素金融股$上涨3.80%。$两倍做多金融股ETF-ProShares$上涨2.49%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"82fa76947202ea24bcb109b846bea089","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","GDXJ","FXP","IONZ","SRPT","NUGT","GDX","IONX","OPEN","NUG","EOSU","RDWU","UYG","IONQ","BK4504","FAS","QID","TIP","LUNR","BK4535","BK4591","SRPU","BK4602","KIE","AGQ","EOSE","BK4170","DRN","YXI","LUNL","RDW","BK4585","SQQQ","PFFR","UGL","TXXS","BK4588","TLT","IYT","IONL","BK4550","VMBS","NU","OPEX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1147732378","title":"异动解读 | Sarepta Therapeutics盘前大跌5.11%，CEO退休及核心疗法安全担忧引发抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1147732378","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147732378?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:07","pubTimestamp":1772107658,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics今日盘前股价大跌5.11%，引发了市场广泛关注。更为关键的是，公司核心产品基因疗法Elevidys面临严重安全挑战，据报道已导致两名患者死亡，且销售额出现下滑。美国食品和药物管理局已要求Sarepta主动停止该疗法的出货，并正对相关死亡事件进行调查。此外，Elevidys的标签已被加上FDA最严重的安全警告，并伴有严格的治疗后监测要求。公司股价在去年已累计下跌82%，此次盘前大跌进一步反映了市场对其未来业务前景与产品管线安全的深切担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107762628","title":"异动解读 | Sarepta Therapeutics夜盘大跌5.32%，CEO退休及疗法安全担忧引抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1107762628","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107762628?lang=zh_cn&edition=full","pubTime":"2026-02-26 09:16","pubTimestamp":1772068596,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics在周三夜盘交易中股价大跌5.32%，市场关注度显著提升。更关键的是，公司核心产品基因疗法Elevidys在2025年面临严峻挑战，包括导致两名患者死亡以及销售额下降。美国食品和药物管理局因此要求Sarepta主动停止该疗法的出货，并正在进行相关死亡事件的调查。Elevidys的标签已被加上FDA最严重的安全警告，并伴有严格的治疗后监测要求。公司股价在去年已累计下跌82%，此次夜盘大跌进一步反映了市场对其未来前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120633627","title":"Sarepta Therapeutics完成2027年票据再融资与重组，整体财务状况及资本结构得到强化","url":"https://stock-news.laohu8.com/highlight/detail?id=1120633627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120633627?lang=zh_cn&edition=full","pubTime":"2026-02-26 05:10","pubTimestamp":1772053810,"startTime":"0","endTime":"0","summary":"在成功完成对2027年到期票据的再融资以及实施结构重组后，Sarepta Therapeutics的全面财务健康状况和资本框架已显著增强。\n此次战略性举措不仅优化了公司的债务期限，还提升了财务灵活性，为未来的研发投入和业务拓展奠定了更为稳固的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4585","IE00BJJMRZ35.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157221741","title":"Sarepta Therapeutics有望在日本实现首笔商业销售后获得4000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1157221741","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157221741?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:11","pubTimestamp":1771942289,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司宣布，其已具备资格在日本市场完成首笔商业化销售后，收取一笔高达4000万美元的里程碑款项。这一财务激励措施与该公司在特定区域的市场拓展进程紧密关联，标志着其国际化战略取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","BK4585","IE00B2B36J28.USD","BK4139","IE00BJJMRZ35.SGD","SRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111784682","title":"财报前瞻｜Sarepta Therapeutics本季度营收预计降37.55%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1111784682","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111784682?lang=zh_cn&edition=full","pubTime":"2026-02-18 13:18","pubTimestamp":1771391931,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics将于2026年02月25日发布最新季度财报，市场关注营收与利润的下行压力及管线进展对商业化前景的影响。市场一致预期本季度营收为3.92亿美元，同比下降37.55%；调整后每股收益为-1.31美元，同比下降169.25%，公司未披露毛利率、净利润或净利率的具体预测，上季度财报亦未给出针对本季度的收入指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Sarepta Therapeutics本季度营收预计降37.55%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161367306","title":"Sarepta Therapeutics宣布其亨廷顿病在研疗法SRP-1005临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1161367306","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161367306?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:32","pubTimestamp":1770211938,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司近日宣布，其针对亨廷顿病的在研治疗药物SRP-1005的临床试验申请已正式获得监管机构批准。这一进展标志着该创新疗法向临床研究阶段迈出了关键一步，为后续开发奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4585","IE0009355771.USD","SRPT","IE00BFTCPJ56.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156120240","title":"Sarepta Therapeutics公司SRP-1005（代号Insightt）首次人体临床试验预计2026年第二季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1156120240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156120240?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:31","pubTimestamp":1770211880,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司宣布，其研发的创新疗法SRP-1005（内部代号Insightt）计划于2026年第二季度开展首次人体临床试验。这项重要进展标志着该药物正式迈入临床研究阶段，为后续开发奠定基础。\n作为公司管线中的重点候选药物，SRP-1005的临床试验启动将遵循严格的科学规范与伦理标准。此次研究旨在评估该疗法在人体中的安全性、耐受性及初步疗效，为未来更大规模的临床研究提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","SRPT","IE00B2B36J28.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4585","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110874705","title":"Sarepta Therapeutics股价盘前大涨6.7% 公司公布杜氏肌营养不良基因疗法三年数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1110874705","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110874705?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:28","pubTimestamp":1769434092,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics股价在盘前交易中强势攀升6.7%，此前该公司公布了其针对杜氏肌营养不良症的基因疗法为期三年的临床数据。这一积极的市场反应凸显了投资者对该疗法长期疗效潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","SRPT","IE0009355771.USD","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162536674","title":"Sarepta公布EMBARK三年期研究积极顶线结果：Elevidys显著延缓杜氏肌营养不良症患者关键功能指标恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1162536674","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162536674?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:04","pubTimestamp":1769432659,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布，其针对ambulatory杜氏肌营养不良症患者开展的EMBARK三年期研究取得积极顶线结果。数据显示，基因疗法Elevidys在关键功能指标上显著延缓了疾病进展。这项长期研究结果进一步验证了该疗法对患者运动功能的持久保护作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B2B36J28.USD","SRPT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":0.0637},{"period":"1month","weight":-0.1355},{"period":"3month","weight":0.0662},{"period":"6month","weight":-0.1626},{"period":"1year","weight":-0.5372},{"period":"ytd","weight":-0.1696}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业化阶段的生物制药公司，专注于发现和开发独特的RNA靶向疗法、基因疗法和其他遗传治疗方式，用于治疗罕见病。它已开发出多种获批的杜氏肌营养不良症治疗药物，并正在推进针对其他神经肌肉和骨骼疾病的候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.052169},{"month":2,"riseRate":0.571429,"avgChangeRate":0.030294},{"month":3,"riseRate":0.5,"avgChangeRate":0.013831},{"month":4,"riseRate":0.285714,"avgChangeRate":0.007228},{"month":5,"riseRate":0.642857,"avgChangeRate":0.112993},{"month":6,"riseRate":0.692308,"avgChangeRate":0.049251},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.004395},{"month":8,"riseRate":0.714286,"avgChangeRate":0.085094},{"month":9,"riseRate":0.571429,"avgChangeRate":0.128993},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.068917},{"month":11,"riseRate":0.714286,"avgChangeRate":0.074513},{"month":12,"riseRate":0.571429,"avgChangeRate":0.010915}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}